Genflow Biosciences plc (GENF.L)

GBp 1.53

(0.0%)

Market Cap (In GBp)

5.33 Million

Revenue (In GBp)

-

Net Income (In GBp)

-1.62 Million

Avg. Volume

342.8 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.323-3.406
PE
-
EPS
-
Beta Value
2.355
ISIN
GB00BP2C3V08
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Eric Jean Leire M.D., MBA
Employee Count
-
Website
https://genflowbio.com
Ipo Date
2022-01-17
Details
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.